• Something wrong with this record ?

Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial

C. Polgár, OJ. Ott, G. Hildebrandt, D. Kauer-Dorner, H. Knauerhase, T. Major, J. Lyczek, JL. Guinot, J. Dunst, CG. Miguelez, P. Slampa, M. Allgäuer, K. Lössl, B. Polat, G. Kovács, AR. Fischedick, R. Fietkau, A. Resch, A. Kulik, L. Arribas, P....

. 2017 ; 18 (2) : 259-268. [pub] 20170114

Language English Country England, Great Britain

Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc17023354
E-resources Online Full text

NLK ProQuest Central from 2000-09-01 to 2 months ago
Nursing & Allied Health Database (ProQuest) from 2000-09-01 to 2 months ago
Health & Medicine (ProQuest) from 2000-09-01 to 2 months ago
Public Health Database (ProQuest) from 2000-09-01 to 2 months ago

Links

PubMed 28094198
DOI 10.1016/s1470-2045(17)30011-6
Knihovny.cz E-resources

BACKGROUND: We previously confirmed the non-inferiority of accelerated partial breast irradiation (APBI) with interstitial brachytherapy in terms of local control and overall survival compared with whole-breast irradiation for patients with early-stage breast cancer who underwent breast-conserving surgery in a phase 3 randomised trial. Here, we present the 5-year late side-effects and cosmetic results of the trial. METHODS: We did this randomised, controlled, phase 3 trial at 16 centres in seven European countries. Women aged 40 years or older with stage 0-IIA breast cancer who underwent breast-conserving surgery with microscopically clear resection margins of at least 2 mm were randomly assigned 1:1, via an online interface, to receive either whole-breast irradiation of 50 Gy with a tumour-bed boost of 10 Gy or APBI with interstitial brachytherapy. Randomisation was stratified by study centre, menopausal status, and tumour type (invasive carcinoma vs ductal carcinoma in situ), with a block size of ten, according to an automated dynamic algorithm. Patients and investigators were not masked to treatment allocation. The primary endpoint of our initial analysis was ipsilateral local recurrence; here, we report the secondary endpoints of late side-effects and cosmesis. We analysed physician-scored late toxicities and patient-scored and physician-scored cosmetic results from the date of breast-conserving surgery to the date of onset of event. Analysis was done according to treatment received (as-treated population). This trial is registered with ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, we randomly assigned 1328 women to receive either whole-breast irradiation (n=673) or APBI with interstitial brachytherapy (n=655); 1184 patients comprised the as-treated population (551 in the whole-breast irradiation group and 633 in the APBI group). At a median follow-up of 6·6 years (IQR 5·8-7·6), no patients had any grade 4 toxities, and three (<1%) of 484 patients in the APBI group and seven (2%) of 393 in the whole-breast irradiation group had grade 3 late skin toxicity (p=0·16). No patients in the APBI group and two (<1%) in the whole-breast irradiation group developed grade 3 late subcutaneous tissue toxicity (p=0·10). The cumulative incidence of any late side-effect of grade 2 or worse at 5 years was 27·0% (95% CI 23·0-30·9) in the whole-breast irradiation group versus 23·3% (19·9-26·8) in the APBI group (p=0·12). The cumulative incidence of grade 2-3 late skin toxicity at 5 years was 10·7% (95% CI 8·0-13·4) in the whole-breast irradiation group versus 6·9% (4·8-9·0) in the APBI group (difference -3·8%, 95% CI -7·2 to 0·4; p=0·020). The cumulative risk of grade 2-3 late subcutaneous tissue side-effects at 5 years was 9·7% (95% CI 7·1-12·3) in the whole-breast irradiation group versus 12·0% (9·4-14·7) in the APBI group (difference 2·4%; 95% CI -1·4 to 6·1; p=0·28). The cumulative incidence of grade 2-3 breast pain was 11·9% (95% CI 9·0-14·7) after whole-breast irradiation versus 8·4% (6·1-10·6) after APBI (difference -3·5%; 95% CI -7·1 to 0·1; p=0·074). At 5 years' follow-up, according to the patients' view, 413 (91%) of 454 patients had excellent to good cosmetic results in the whole-breast irradiation group versus 498 (92%) of 541 patients in the APBI group (p=0·62); when judged by the physicians, 408 (90%) of 454 patients and 503 (93%) of 542 patients, respectively, had excellent to good cosmetic results (p=0·12). No treatment-related deaths occurred, but six (15%) of 41 patients (three in each group) died from breast cancer, and 35 (85%) deaths (21 in the whole-breast irradiation group and 14 in the APBI group) were unrelated. INTERPRETATION: 5-year toxicity profiles and cosmetic results were similar in patients treated with breast-conserving surgery followed by either APBI with interstitial brachytherapy or conventional whole-breast irradiation, with significantly fewer grade 2-3 late skin side-effects after APBI with interstitial brachytherapy. These findings provide further clinical evidence for the routine use of interstitial multicatheter brachytherapy-based APBI in the treatment of patients with low-risk breast cancer who opt for breast conservation. FUNDING: German Cancer Aid.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023354
003      
CZ-PrNML
005      
20170720123520.0
007      
ta
008      
170720s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1470-2045(17)30011-6 $2 doi
035    __
$a (PubMed)28094198
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Polgár, Csaba $u Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. Electronic address: polgar@oncol.hu.
245    10
$a Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial / $c C. Polgár, OJ. Ott, G. Hildebrandt, D. Kauer-Dorner, H. Knauerhase, T. Major, J. Lyczek, JL. Guinot, J. Dunst, CG. Miguelez, P. Slampa, M. Allgäuer, K. Lössl, B. Polat, G. Kovács, AR. Fischedick, R. Fietkau, A. Resch, A. Kulik, L. Arribas, P. Niehoff, F. Guedea, A. Schlamann, R. Pötter, C. Gall, W. Uter, V. Strnad, . ,
520    9_
$a BACKGROUND: We previously confirmed the non-inferiority of accelerated partial breast irradiation (APBI) with interstitial brachytherapy in terms of local control and overall survival compared with whole-breast irradiation for patients with early-stage breast cancer who underwent breast-conserving surgery in a phase 3 randomised trial. Here, we present the 5-year late side-effects and cosmetic results of the trial. METHODS: We did this randomised, controlled, phase 3 trial at 16 centres in seven European countries. Women aged 40 years or older with stage 0-IIA breast cancer who underwent breast-conserving surgery with microscopically clear resection margins of at least 2 mm were randomly assigned 1:1, via an online interface, to receive either whole-breast irradiation of 50 Gy with a tumour-bed boost of 10 Gy or APBI with interstitial brachytherapy. Randomisation was stratified by study centre, menopausal status, and tumour type (invasive carcinoma vs ductal carcinoma in situ), with a block size of ten, according to an automated dynamic algorithm. Patients and investigators were not masked to treatment allocation. The primary endpoint of our initial analysis was ipsilateral local recurrence; here, we report the secondary endpoints of late side-effects and cosmesis. We analysed physician-scored late toxicities and patient-scored and physician-scored cosmetic results from the date of breast-conserving surgery to the date of onset of event. Analysis was done according to treatment received (as-treated population). This trial is registered with ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, we randomly assigned 1328 women to receive either whole-breast irradiation (n=673) or APBI with interstitial brachytherapy (n=655); 1184 patients comprised the as-treated population (551 in the whole-breast irradiation group and 633 in the APBI group). At a median follow-up of 6·6 years (IQR 5·8-7·6), no patients had any grade 4 toxities, and three (<1%) of 484 patients in the APBI group and seven (2%) of 393 in the whole-breast irradiation group had grade 3 late skin toxicity (p=0·16). No patients in the APBI group and two (<1%) in the whole-breast irradiation group developed grade 3 late subcutaneous tissue toxicity (p=0·10). The cumulative incidence of any late side-effect of grade 2 or worse at 5 years was 27·0% (95% CI 23·0-30·9) in the whole-breast irradiation group versus 23·3% (19·9-26·8) in the APBI group (p=0·12). The cumulative incidence of grade 2-3 late skin toxicity at 5 years was 10·7% (95% CI 8·0-13·4) in the whole-breast irradiation group versus 6·9% (4·8-9·0) in the APBI group (difference -3·8%, 95% CI -7·2 to 0·4; p=0·020). The cumulative risk of grade 2-3 late subcutaneous tissue side-effects at 5 years was 9·7% (95% CI 7·1-12·3) in the whole-breast irradiation group versus 12·0% (9·4-14·7) in the APBI group (difference 2·4%; 95% CI -1·4 to 6·1; p=0·28). The cumulative incidence of grade 2-3 breast pain was 11·9% (95% CI 9·0-14·7) after whole-breast irradiation versus 8·4% (6·1-10·6) after APBI (difference -3·5%; 95% CI -7·1 to 0·1; p=0·074). At 5 years' follow-up, according to the patients' view, 413 (91%) of 454 patients had excellent to good cosmetic results in the whole-breast irradiation group versus 498 (92%) of 541 patients in the APBI group (p=0·62); when judged by the physicians, 408 (90%) of 454 patients and 503 (93%) of 542 patients, respectively, had excellent to good cosmetic results (p=0·12). No treatment-related deaths occurred, but six (15%) of 41 patients (three in each group) died from breast cancer, and 35 (85%) deaths (21 in the whole-breast irradiation group and 14 in the APBI group) were unrelated. INTERPRETATION: 5-year toxicity profiles and cosmetic results were similar in patients treated with breast-conserving surgery followed by either APBI with interstitial brachytherapy or conventional whole-breast irradiation, with significantly fewer grade 2-3 late skin side-effects after APBI with interstitial brachytherapy. These findings provide further clinical evidence for the routine use of interstitial multicatheter brachytherapy-based APBI in the treatment of patients with low-risk breast cancer who opt for breast conservation. FUNDING: German Cancer Aid.
650    _2
$a senioři $7 D000368
650    _2
$a brachyterapie $x škodlivé účinky $7 D001918
650    _2
$a nádory prsu $x patologie $x radioterapie $x chirurgie $7 D001943
650    _2
$a duktální karcinom prsu $x patologie $x radioterapie $x chirurgie $7 D018270
650    _2
$a intraduktální neinfiltrující karcinom $x patologie $x radioterapie $x chirurgie $7 D002285
650    _2
$a lobulární karcinom $x patologie $x radioterapie $x chirurgie $7 D018275
650    _2
$a kombinovaná terapie $7 D003131
650    12
$a kosmetické přípravky $7 D003358
650    _2
$a tuková nekróza $x diagnóza $x etiologie $7 D005218
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mastektomie $x škodlivé účinky $7 D008408
650    _2
$a segmentální mastektomie $x škodlivé účinky $7 D015412
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a staging nádorů $7 D009367
650    _2
$a prognóza $7 D011379
650    _2
$a radiodermatitida $x diagnóza $x etiologie $7 D011855
650    _2
$a celková dávka radioterapie $7 D011879
650    _2
$a časové faktory $7 D013997
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ott, Oliver J $u Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.
700    1_
$a Hildebrandt, Guido $u Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
700    1_
$a Kauer-Dorner, Daniela $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria.
700    1_
$a Knauerhase, Hellen $u Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
700    1_
$a Major, Tibor $u Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
700    1_
$a Lyczek, Jaroslaw $u Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland; Podkarpacki Hospital Cancer Center Brzozów, Brzozów, Poland.
700    1_
$a Guinot, José Luis $u Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain.
700    1_
$a Dunst, Jürgen $u Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany.
700    1_
$a Miguelez, Cristina Gutierrez $u Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Allgäuer, Michael $u Department of Radiation Oncology, Hospital Barmherzige Brüder, Regensburg, Germany. $7 gn_A_00004514
700    1_
$a Lössl, Kristina $u Department of Radiation Oncology, University Hospital Bern, Inselspital, Switzerland.
700    1_
$a Polat, Bülent $u Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany.
700    1_
$a Kovács, György $u Interdisciplinary Brachytherapy Unit, University of Lübeck/Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany.
700    1_
$a Fischedick, Arnt-René $u Department of Radiation Oncology, Clemens Hospital, Münster, Germany.
700    1_
$a Fietkau, Rainer $u Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany.
700    1_
$a Resch, Alexandra $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria.
700    1_
$a Kulik, Anna $u Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland.
700    1_
$a Arribas, Leo $u Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain. $7 gn_A_00008867
700    1_
$a Niehoff, Peter $u Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany; Department of Radiotherapy, Sana Hospital Offenbach, Offenbach, Germany.
700    1_
$a Guedea, Ferran $u Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.
700    1_
$a Schlamann, Annika $u Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany.
700    1_
$a Pötter, Richard $u Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria.
700    1_
$a Gall, Christine $u Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Uter, Wolfgang $u Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany.
700    1_
$a Strnad, Vratislav $u Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.
700    1_
$a ,
773    0_
$w MED00011558 $t The Lancet. Oncology $x 1474-5488 $g Roč. 18, č. 2 (2017), s. 259-268
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28094198 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170720124013 $b ABA008
999    __
$a ok $b bmc $g 1239035 $s 984267
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 18 $c 2 $d 259-268 $e 20170114 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options